BMT2

Across TCGA pan-cancer cohorts, BMT2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BMT2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where BMT2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BMT2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where BMT2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BMT2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.496	<.001	8	view →
LUAD	All	II,III,IV	+0.352	<.001	7	view →
HNSC	Male	II,III,IV	+0.243	.011	4	view →
PDAC	Male	All	−1.340	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BMT2–LSCC

Open the LSCC breakdown →